![](/img/cover-not-exists.png)
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma
Kumar, Shaji K., Grzasko, Norbert, Delimpasi, Sosana, Jedrzejczak, Wieslaw W., Grosicki, Sebastian, Kyrtsonis, Marie-Christine, Spencer, Andrew, Gupta, Neeraj, Teng, Zhaoyang, Byrne, Catriona, LabotkaLanguage:
english
Journal:
British Journal of Haematology
DOI:
10.1111/bjh.15679
Date:
November, 2018
File:
PDF, 265 KB
english, 2018